BridgeBio Pharma, Inc. (BBIO), a company focused on genetic diseases and cancers, on Wednesday announced the pricing of public offering of 8,620,690 shares at $29 per share, to raise about $250 million. The drug maker has granted the underwriters a 30-day option to purchase up to an additional 1,293,103 shares. BridgeBio said the offering is scheduled to close on or about March 8.
J.P. Morgan, Cantor and Mizuho are acting as joint book-running managers, whereas Raymond James is acting as lead manager.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.